Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck KGaA And Novartis Back In Horse Race For First Oral MS Drug To Market

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA granted the reworked cladribine NDA submitted in June by U.S. affiliate EMD Serono a six-month priority review, with approval possible in the fourth quarter, while action is anticipated on Gilenia in September.

You may also be interested in...



Merck KGaA Turns To Outsider Oschmann To Head Pharma Unit

Merck & Co.'s emerging markets head Stefan Oschmann will succeed Merck KGaA's Elmar Schnee as head of pharmaceuticals effective Jan. 1.

Merck KGaA Turns To Outsider Oschmann To Head Pharma Unit

Merck & Co.'s emerging markets head Stefan Oschmann will succeed Merck KGaA's Elmar Schnee as head of pharmaceuticals effective Jan. 1.

EU Regulators Reject Merck KGaA's Oral MS Drug Cladribine

Surprise rejection hits German drugmaker hard and casts doubt over FDA approval.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS070974

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel